A 'Reverse Aging' Guru's Trail of Failed Businesses

Wall Street Journal investigation into the commercial track record of companies David Sinclair founded, reporting they raised more than $1 billion in aggregate while four have gone bankrupt or largely halted operations and another four have not completed human testing of their products. WSJ is paywalled and could not be directly fetched by the automated browser in this session; byline, headline, and substance independently corroborated via a directly-fetched syndication (bioethics.com, dated 6 December 2024), which reproduces the '$1 billion... four companies... gone bankrupt or largely halted operations... another four either haven't yet tested their drugs or gene therapies in humans' language, and via a stem-cell-biologist commentary (ipscell.com, Paul Knoepfler, 10 December 2024) naming the companies discussed (Sirtris, CohBar, OvaScience, Life Biosciences, Tally Health) and the byline 'Amy Marcus.' Used in this bundle only for the two facts corroborated in the fetched bioethics.com syndication; no verbatim WSJ quotation appears in the bundle.